Gerald Wolfgang Prager

21PUBLICATIONS
96CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsCancer cell biologyPredictive and prognostic markersEnvironmental epidemiology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (21)

|Aug 12, 2026
Outcomes of Cisplatin, Gemcitabine, and Durvalumab According to TOPAZ-1 Study Eligibility: A Large Global Analysis in a Real-World Setting.

|Jul 29, 2026
Exploring the Role of Surgery After Systemic Therapy in Locally Advanced Biliary Tract Cancer: Outcomes From a Large Retrospective Multinational Real-World Cohort Treated With Cisplatin, Gemcitabine, and Durvalumab.

|Jun 25, 2026
Biomarker analysis from patients with metastatic PDAC treated with TGFβ antibody, NIS793, plus abraxane+gemcitabine vs. abraxane+gemcitabine alone in a phase II, open label, randomized study.

|Oct 08, 2025
Opportunities and Approaches to Optimising Advanced Cholangiocarcinoma Outcomes in the Era of Targeted Therapies: A Narrative Review.

Teresa Macarulla, Cindy Neuzillet, Gerald W Prager

|Sep 09, 2025
Prospective validation of the modified metastatic colorectal cancer score (mCCS) in >600 patients with RAS-wild-type metastatic colorectal cancer treated with first-line panitumumab plus FOLFIRI/FOLFOX: Final results of the non-interventional study VALIDATE.

Karin Potthoff, Jens Uhlig, Lutz Jacobasch

|Aug 29, 2025
Lack of association between prior or concurrent malignancies and overall survival in gastroesophageal cancer: evidence from a large European single-center cohort.

Hannah C Puhr, Luzia Berchtold, Linda Zingerle

Pageof 4

Frequent Collaborators

4 joint publications

Anna S Berghoff

4 joint publications

Monica Niger

4 joint publications

Hannah C Puhr

4 joint publications

Matthias Preusser